Showing 1351-1360 of 1554 results for "".
- Prospective Study for NaturalVue Multifocal Demonstrates Decreased Refractive Error Change in Fast-Progressing Myopic Childrenhttps://modernod.com/news/prospective-study-for-naturalvue-multifocal-demonstrates-decreased-refractive-error-change-in-fast-progressing-myopic-children/2479681/Thomas Aller, OD, presented updated findings from a prospective clinical trial of NaturalVue (etafilcon A) 1 Day Multifocal Contact Lenses at a briefing for media and industry leaders at the American Academy of Optometry (AAO) Conference in San Antonio on November 9. The NaturalVue portfolio of p
- Non-Contact Panretinal Photocoagulation for Navilas 577s Introduced at AAO 2018https://modernod.com/news/non-contact-panretinal-photocoagulation-for-navilas-577s-introduced-at-aao-2018/2479753/At the AAO 2018 meeting in Chicago, OD-OS is launching a new widefield objective which brings non-contact panretinal photocoagulation with access to the far periphery (ora serrata) to the Navilas 577s Laser System. The new option for peripheral treatments can further enhance compliance of sensiti
- Clearside Biomedical Expands Patent Portfolio in the US and Europehttps://modernod.com/news/clearside-biomedical-expands-patent-portfolio-in-the-us-and-europe/2478203/Clearside Biomedical announced the recent issuance of three additional patents in the United States and Europe. The United States Patent and Trademark Office (USPTO) recently granted patent number 10,722,396 to Clearside. This patent covers Clearside’s SCS M
- Atia Vision Announces Upcoming Presentations Highlighting Modular Presbyopia-Correcting IOL Technologyhttps://modernod.com/news/atia-vision-announces-upcoming-presentations-highlighting-modular-presbyopia-correcting-iol-technology/2476867/Atia Vision announced its technology will be featured in presentations at two ophthalmology conferences this week in Paris, France. The first presentation will be delivered by the company during the Ophthalmology Futures European Forum, a clinician-driven global m
- Avedro Announces Comprehensive Educational Schedule at ASCRS Annual Meetinghttps://modernod.com/news/avedro-announces-comprehensive-educational-schedule-at-ascrs-annual-meeting/2476513/Avedro announced the inclusion of a wide range of corneal cross-linking and keratoconus scientific and educational programs at the 2019 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting held M
- Johnson & Johnson Vision Highlights New Data at 2018 ARVO Annual Meetinghttps://modernod.com/news/johnson-johnson-vision-highlights-new-data-at-2018-arvo-annual-meeting/2480201/Johnson & Johnson Vision announced that a suite of new research from its eye health portfolio will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Honolulu, Hawaii from April 29 to M
- Ophthalmic World Leaders (OWL) Names First MD President and Other Leadership Changes for 2026https://modernod.com/news/ophthalmic-world-leaders-owl-names-first-md-president-and-other-leadership-changes-for-2026/2484293/Ophthalmic World Leaders (OWL) announces the appointment of Renee Bovelle, MD, as its new President. OWL also welcomes three new members to its Board of Directors: Kevin M. Douglas, MD (Medical Director, Eye Care – Retina, AbbVie), Maáza Martin (S
- Tilak Receives Positive Opinion in Europe for Early Reimbursement of Odysight Telemonitoring Devicehttps://modernod.com/news/tilak-receives-positive-opinion-for-early-reimbursement-of-odysight-telemonitoring-device/2484169/Paris-based Tilak Healthcare has received a positive opinion from the French National Health Authority (Haute Autorité de Santé, HAS) for the reimbursement of Odysight under the PECAN (Prise En Charge Anticipée des dispositifs m&
- Bausch + Lomb Launches Lumify Preservative Free Redness Reliever Eye Drops in the UShttps://modernod.com/news/bausch-lomb-launches-lumify-preservative-free-redness-reliever-eye-drops-in-the-united-states/2482814/Bausch + Lomb announced the US launch of Lumify Preservative Free redness reliever eye drops, which the company describes as the first and only preservative-free over-the-counter (OTC) eye drops with low-dose brimonidine tartrate 0.025% that relieve redness of the eye due to m
- Sydnexis Announces Positive CHMP Opinion in Europe for Myopia Drug Candidate SYD-101https://modernod.com/news/sydnexis-announces-positive-chmp-opinion-in-europe-for-myopia-drug-candidate-syd-101/2482722/Sydnexis announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion for its proprietary low-dose atropine formulation, SYD-101, for slowing the progression of pediatric m